



# AMPLIFYING THE SUCCESS OF CANCER IMMUNOTHERAPY

---

## Making Tumors “Hot” with Bryostatin


Sam Kongsamut, PhD  
Co-founder, VP R&D  
[skongsamut@bryologyx.com](mailto:skongsamut@bryologyx.com)

JUNE 2019



# Inadequate antigen expression is a key reason for immuno-oncology drug failure


Cancer cells are not visible (COLD) when tumor antigen density is low



\* Representation of Liquid Tumors

# BryoLogyx's bryostatin enhances tumor antigen expression

Increases (HOT) targets for immune system recognition




\* Representation of Liquid Tumors

# NCI *in vivo* proof of concept study

Substantially more effective w/bryostatin

Bryostatin enhances CD22 CART tumor clearance and survival



- Additional antigens upregulated
- Immune effector functions under investigation

NCI to advance IO with Bryostatin to phase 1b clinical study in 2019

\*Representation of both liquid and hard tumors

# BryoLogyx's exclusive opportunity to improve I/O responses

## Science

“This synthesis can thus readily supply the amount of material needed to further advance clinical evaluation, as a single gram of bryostatin 1 can treat 1,000 cancer patients”

October 13, 2017

- ✓ Exclusive global rights from Stanford to bryostatin synthesis method for use in cancer and HIV
- ✓ Synthetic process eliminates dependence on costly, unreliable marine sourced bryostatin
- ✓ BryoLogyx has reproduced synthetic process
- ✓ Analog development offers optimized treatments and new IP



# Corporate strategy

1. Focus on 3 hematologic malignancies and identified antigens initially

Multiple myeloma (MM), Acute Myelogenous Leukemia (AML); Non-Hodgkin's Lymphoma (NHL)

2. Develop collaborations/partnerships around potential pairings

3. Expand Bryostatin/I-O combinations solid/other liquid tumors

4. Advance next generation bryostatin analogs

5. Leverage NCI's clinical research

6. Expand IP estate